Skip to content
MARKETS / NASDAQ / CRMD
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

CorMedix Inc. CRMD

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$311.7M
▲ 617.0% YoY
$163.1M
$172.8M
Growth
USD 311.7M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 311.7 · Net income 163.1
200M2007201020132016201920222025
Compound annual growth
+1582.8%
+319.7%
+107.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +319.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
52 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 48.2% · Net 52.3%
-200000%-400000%2007201020132016201920222025
ROE
FY2025 · ROE 66.6%
-200%-400%-600%2007201020132016201920222025

Each USD of equity produced 67 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 172.8
80M160M-20M-40M2007201020132016201920222025

Total assetsUSD 826.1M
EquityUSD 405.3M
CashUSD 144.8M
Current ratio2.11×

Equity funds 49% of total assets.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.30.0·0.00.00.00.00.00.00.00.00.00.00.0·····
Operating income $B0.2−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
EBITDA $B0.2−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
Income tax $B−0.0−0.0·−0.0−0.0−0.0−0.0·····0.00.0−0.0−0.0···
Net income $B0.2−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.2−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
EPS, diluted $2.04−0.30−0.91−0.74−0.75−0.77−1.80−1.51−0.60−0.65−0.58−0.96−0.69−0.30−0.58−1.15···
Dividend / sh $···················
Payout %···················
ROE %66.6−23.2−74.0−50.4−52.7−64.9−115.0−442.5−264.0−95.1−96.6··−678.7−155.4····
Shares out B0.080.060.050.040.040.030.030.020.070.040.040.020.020.010.010.01···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 4 divergences in 79 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures4 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image